Details of the Drug

General Information of Drug (ID: DMOPZDT)

Drug Name
Perindopril
Synonyms
ACEON; Coverex; Coversum; Coversyl; Prestarium; Coverene Cor; Cpd with unspecified MF; Aceon (TN); Acertil (TN); Armix (TN); Coverene (TN); Coverex (TN); Coversum (TN); DW-7950; Prestarium (TN); Prexanil (TN); Prexum (TN); Procaptan (TN); S-9490; SED-9490; McN-A-2833; Perindopril (USAN/INN); Ethyl N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvalinate; (2S)-2-[(1S)-1-Carbethoxybutylamino]-1-oxopropyl-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1]
Therapeutic Class
Antihypertensive Agents
Affected Organisms
Humans and other mammals
ATC Code
C09AA04: Perindopril
C09AA: ACE inhibitors, plain
C09A: ACE INHIBITORS, PLAIN
C09: AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 368.5
Logarithm of the Partition Coefficient (xlogp) 0.9
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Elimination
8% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.2 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.60385 micromolar/kg/day [4]
Chemical Identifiers
Formula
C19H32N2O5
IUPAC Name
(2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
Canonical SMILES
CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O
InChI
InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1
InChIKey
IPVQLZZIHOAWMC-QXKUPLGCSA-N
Cross-matching ID
PubChem CID
107807
ChEBI ID
CHEMBL1581
CAS Number
82834-16-0
UNII
Y5GMK36KGY
DrugBank ID
DB00790
TTD ID
D03KYG
VARIDT ID
DR00058
ACDINA ID
D00520
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Inhibitor [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [6]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Gene/Protein Processing [7]
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [8]
von Willebrand factor OTNMMA2P VWF_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hypertension
ICD Disease Classification BA00-BA04
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiotensin-converting enzyme (ACE) DTT SLC33A1 2.62E-01 -0.01 -0.06
Peptide transporter 1 (SLC15A1) DTP PEPT1 6.91E-01 8.30E-03 7.24E-02
Peptide transporter 2 (SLC15A2) DTP PEPT2 8.33E-02 -3.63E-02 -1.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Perindopril
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Eprosartan DM07K2I Major Increased risk of hyperkalemia by the combination of Perindopril and Eprosartan. Hypertension [BA00-BA04] [10]
Aliskiren DM1BV7W Major Increased risk of hyperkalemia by the combination of Perindopril and Aliskiren. Hypertension [BA00-BA04] [11]
TAK-491 DMCF6SX Major Increased risk of hyperkalemia by the combination of Perindopril and TAK-491. Hypertension [BA00-BA04] [10]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Perindopril and Trichlormethiazide. Hypertension [BA00-BA04] [12]
Telmisartan DMS3GX2 Major Increased risk of hyperkalemia by the combination of Perindopril and Telmisartan. Hypertension [BA00-BA04] [10]
Irbesartan DMTP1DC Major Increased risk of hyperkalemia by the combination of Perindopril and Irbesartan. Hypertension [BA00-BA04] [13]
Hydrochlorothiazide DMUSZHD Moderate Additive hypotensive effects by the combination of Perindopril and Hydrochlorothiazide. Hypertension [BA00-BA04] [12]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Perindopril (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Perindopril and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [14]
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Perindopril due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [15]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Perindopril and Repaglinide. Acute diabete complication [5A2Y] [16]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Perindopril and Glibenclamide. Acute diabete complication [5A2Y] [16]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Perindopril and Tolazamide. Acute diabete complication [5A2Y] [16]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Perindopril and Insulin-glulisine. Acute diabete complication [5A2Y] [16]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Perindopril and Insulin-aspart. Acute diabete complication [5A2Y] [17]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Perindopril and Glipizide. Acute diabete complication [5A2Y] [16]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Perindopril and Isosorbide dinitrate. Anal fissure/fistula [DB50] [18]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Perindopril and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [19]
Gentamicin DMKINJO Minor Increased risk of nephrotoxicity by the combination of Perindopril and Gentamicin. Bacterial infection [1A00-1C4Z] [20]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Perindopril and Cariprazine. Bipolar disorder [6A60] [21]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Perindopril and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [22]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Perindopril and Drospirenone. Contraceptive management [QA21] [23]
Ardeparin DMYRX8B Moderate Increased risk of hyperkalemia by the combination of Perindopril and Ardeparin. Coronary thrombosis [BA43] [10]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Perindopril and Selegiline. Depression [6A70-6A7Z] [24]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Perindopril and OPC-34712. Depression [6A70-6A7Z] [21]
SODIUM CITRATE DMHPD2Y Minor Decreased absorption of Perindopril due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [15]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Perindopril and Cannabidiol. Epileptic encephalopathy [8A62] [25]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Perindopril and Ethacrynic acid. Essential hypertension [BA00] [26]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Perindopril and Phenoxybenzamine. Essential hypertension [BA00] [27]
Acetazolamide DM1AF5U Moderate Additive hypotensive effects by the combination of Perindopril and Acetazolamide. Glaucoma [9C61] [12]
Dichlorphenamide DMH7IDQ Moderate Additive hypotensive effects by the combination of Perindopril and Dichlorphenamide. Glaucoma [9C61] [26]
Chlorothiazide DMLHESP Moderate Additive hypotensive effects by the combination of Perindopril and Chlorothiazide. Heart failure [BD10-BD1Z] [12]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Perindopril and Bumetanide. Heart failure [BD10-BD1Z] [12]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Perindopril and Procarbazine. Hodgkin lymphoma [2B30] [24]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Perindopril and Brentuximab vedotin. Hodgkin lymphoma [2B30] [28]
Didanosine DMI2QPE Minor Decreased absorption of Perindopril due to altered gastric pH caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [15]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Perindopril and Isosorbide mononitrate. Hydrocephalus [8D64] [18]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Perindopril and Mipomersen. Hyper-lipoproteinaemia [5C80] [29]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Perindopril and Teriflunomide. Hyper-lipoproteinaemia [5C80] [30]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Perindopril and BMS-201038. Hyper-lipoproteinaemia [5C80] [31]
Tolvaptan DMIWFRL Moderate Increased risk of hyperkalemia by the combination of Perindopril and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [32]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Perindopril and ITI-007. Insomnia [7A00-7A0Z] [21]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Perindopril and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [33]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Perindopril and Idelalisib. Mature B-cell leukaemia [2A82] [34]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Perindopril due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [30]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Perindopril and Ozanimod. Multiple sclerosis [8A40] [24]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Perindopril and Promethazine. Nausea/vomiting [MD90] [21]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Perindopril and Polythiazide. Oedema [MG29] [12]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Perindopril and Rasagiline. Parkinsonism [8A00] [24]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Perindopril and Terazosin. Prostate hyperplasia [GA90] [27]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Perindopril and Silodosin. Prostate hyperplasia [GA90] [27]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Perindopril and Levomepromazine. Psychotic disorder [6A20-6A25] [21]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Perindopril and Leflunomide. Rheumatoid arthritis [FA20] [30]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Perindopril and Quetiapine. Schizophrenia [6A20] [21]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Perindopril and Mesoridazine. Schizophrenia [6A20] [21]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Perindopril and Aripiprazole. Schizophrenia [6A20] [21]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Perindopril and Iloperidone. Schizophrenia [6A20] [21]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Perindopril and Paliperidone. Schizophrenia [6A20] [21]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Perindopril and Perphenazine. Schizophrenia [6A20] [21]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Perindopril and Molindone. Schizophrenia [6A20] [21]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Perindopril and Thiothixene. Schizophrenia [6A20] [21]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Perindopril and Trifluoperazine. Schizophrenia [6A20] [21]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Perindopril and Amisulpride. Schizophrenia [6A20] [21]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Perindopril and Asenapine. Schizophrenia [6A20] [21]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Perindopril and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [25]
Tacrolimus DMZ7XNQ Moderate Increased risk of hyperkalemia by the combination of Perindopril and Tacrolimus. Transplant rejection [NE84] [35]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Perindopril and Tolbutamide. Type 2 diabetes mellitus [5A11] [16]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Perindopril and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [16]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Perindopril and Methdilazine. Vasomotor/allergic rhinitis [CA08] [21]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Perindopril and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [36]
⏷ Show the Full List of 62 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd E00585 56841934 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Perindopril 4 mg tablet 4 mg Oral Tablet Oral
Perindopril 8 mg tablet 8 mg Oral Tablet Oral
Perindopril 2 mg tablet 2 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6367).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
6 Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
7 The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines. Int J Clin Pharmacol Ther. 2009 Nov;47(11):686-94. doi: 10.5414/cpp47686.
8 Experience with perindopril in normal volunteers. Arch Mal Coeur Vaiss. 1989 May;82 Spec No 1:35-41.
9 Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J. 2002 Sep;66(9):811-5. doi: 10.1253/circj.66.811.
10 Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
11 Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
12 Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
13 Product Information. Micardis (telmisartan). Boehringer-Ingelheim, Ridgefield, CT.
14 Cerner Multum, Inc. "Australian Product Information.".
15 Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
16 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
17 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
18 Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
19 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
20 Product Information. Aceon (perindopril). Solvay Pharmaceuticals Inc, Marietta, GA.
21 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
22 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
23 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
24 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
25 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
26 Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
27 Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
28 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
29 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
30 Canadian Pharmacists Association.
31 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
32 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
33 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
34 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
35 Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
36 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.